JPMorgan Chase & Co's Amendment to Schedule 13G/A for Bristol-Myers Squibb Company

JPMorgan Chase & Co filed an amendment to its Schedule 13G/A for Bristol-Myers Squibb Company, reporting a decrease in its ownership. As of September 30, 2025, JPMorgan Chase & Co beneficially owns 81,890,781 shares, representing 4.0% of the common stock. This marks a decrease of 22,070,093 shares from the previous filing, with the value of the holdings dropping by approximately $1.04 billion. The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer. The amendment was signed by Rachel Tsvaygoft, Vice President of JPMorgan Chase & Co.